You are currently viewing the summary.
See the full text- Join / Subscribe
- Buy article
- member account Enable
- Renew subscription
- Recommend a subscription to your library
- Help for librarians
Summary
Millions fear the occurrence of migraine headaches, which affect about 12% of the world population at least once a year. Existing treatments can ward off migraines after starting, and does not work for many people. On the horizon, however, is a new class of drugs that many scientists believe can stop migraines at their root. Four pharmaceutical companies are racing to complete advanced clinical testing for antibody drugs that block the activity of a molecule called calcitonin gene-related peptide, or CGRP, which peaks during migraine attacks. The discovery of CGRP can also help solve the age-old puzzle of what triggers complex neurological event of a migraine.
0 Komentar